Noxafil Approval History
- FDA approved: Yes (First approved September 15th, 2006)
- Brand name: Noxafil
- Generic name: posaconazole
- Company: Schering-Plough Corporation
- Treatment for: Aspergillosis, Invasive, Candida Infections, Systemic, Oral Thrush
Noxafil is a triazole antifungal agent indicated for the prophylaxis of invasive Aspergillus and Candida infections in patients 13 years of age and older who are at high risk of developing these infections due to being severely immunocompromised, such as hematopoietic stem cell transplant (HSCT) recipients with graft-versus-host disease (GVHD) or those with hematologic malignancies with prolonged neutropenia from chemotherapy.
FDA Approval History for Noxafil
|Sep 15, 2006||Noxafil Schering-Plough Corporation - Treatment for Prevention of Invasive Fungal Infections|
|Jul 13, 2004||Schering-Plough Reports Posaconazole NDA Accepted for FDA Review|
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.